Rein Therapeutics Inc.
RNTX
$1.16
$0.043.57%
NASDAQ
| 12/31/2025 | 09/30/2025 | ||||
|---|---|---|---|---|---|
| Revenue | -- | -- | |||
| Total Other Revenue | -- | -- | |||
| Total Revenue | -- | -- | |||
| Cost of Revenue | -- | -- | |||
| Gross Profit | -- | -- | |||
| SG&A Expenses | -48.62% | 47.77% | |||
| Depreciation & Amortization | -- | -- | |||
| Other Operating Expenses | -- | -- | |||
| Total Operating Expenses | -27.91% | -20.07% | |||
| Operating Income | 27.91% | 20.07% | |||
| Income Before Tax | -485.54% | 18.19% | |||
| Income Tax Expenses | -- | -- | |||
| Earnings from Continuing Operations | -472.78% | 18.19% | |||
| Earnings from Discontinued Operations | -- | -- | |||
| Extraordinary Item & Accounting Change | -- | -- | |||
| Minority Interest in Earnings | -- | -- | |||
| Net Income | -472.78% | 18.19% | |||
| EBIT | 27.91% | 20.07% | |||
| EBITDA | 27.91% | 20.06% | |||
| EPS Basic | -415.97% | 24.93% | |||
| Normalized Basic EPS | 35.75% | 24.96% | |||
| EPS Diluted | -415.97% | 24.93% | |||
| Normalized Diluted EPS | 35.75% | 24.96% | |||
| Average Basic Shares Outstanding | 11.02% | 8.99% | |||
| Average Diluted Shares Outstanding | 11.02% | 8.99% | |||
| Dividend Per Share | -- | -- | |||
| Payout Ratio | -- | -- | |||